T1	Participants 165 225	Cooperative Group of Study and Treatment of Multiple Myeloma
T2	Participants 475 549	Patients with untreated stage I MM (defined according to Durie and Salmon)
T3	Participants 948 1144	responsive patients were randomised between receiving additional therapy only until maximal tumour reduction was reached (plateau phase) and continuing induction therapy indefinitely until relapse
T4	Participants 1196 1297	patients originally treated with MPH-P for induction received combination chemotherapy and vice versa
T5	Participants 2814 2956	the overwhelming majority of patients with MM can safely be given MPH-P as first therapy, and this treatment may be delayed in early diseases.
